Cargando…
Practical guidance for the evaluation of disease progression and the decision to change treatment in patients with advanced gastric cancer receiving chemotherapy
After failure of first-line chemotherapy with fluoropyrimidines and platinum compounds for advanced gastric cancer, second-line chemotherapy with ramucirumab plus paclitaxel, which elicits a durable response, and third-line or later chemotherapy with nivolumab have been shown to lead to a more favor...
Autores principales: | Iwasa, Satoru, Kudo, Toshihiro, Takahari, Daisuke, Hara, Hiroki, Kato, Ken, Satoh, Taroh |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Singapore
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7329754/ https://www.ncbi.nlm.nih.gov/pubmed/32347434 http://dx.doi.org/10.1007/s10147-020-01684-z |
Ejemplares similares
-
A Case of Advanced Gastric Cancer with Poor Performance Status Which Improved by Chemotherapy
por: Shitara, Kohei, et al.
Publicado: (2010) -
Fluoropyrimidine with or without platinum as first-line chemotherapy in patients with advanced gastric cancer and severe peritoneal metastasis: a multicenter retrospective study
por: Arai, Hiroyuki, et al.
Publicado: (2019) -
A Phase I study of pevonedistat plus capecitabine plus oxaliplatin in patients with advanced gastric cancer refractory to platinum (NCCH-1811)
por: Shoji, Hirokazu, et al.
Publicado: (2021) -
Phase 1 trial of avelumab (anti-PD-L1) in Japanese patients with advanced solid tumors, including dose expansion in patients with gastric or gastroesophageal junction cancer: the JAVELIN Solid Tumor JPN trial
por: Doi, Toshihiko, et al.
Publicado: (2018) -
The peripheral immune status of granulocytic myeloid-derived suppressor cells correlates the survival in advanced gastric cancer patients receiving cisplatin-based chemotherapy
por: Shoji, Hirokazu, et al.
Publicado: (2017)